Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer

NCT01856920 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT01856920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01856920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer
Lead sponsor
NantCell, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 26, 2013
Completion date
May 8, 2018
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer (mtc)